POPULATION PK AND EXPOSURE-RESPONSE ANALYSES OF APREMILAST IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS

被引：0
|
作者：
Kassir, N. [1 ]
Savant, I. [2 ]
Mouksassi, M. S. [1 ]
Marier, J. F. [1 ]
Zhu, W. [2 ]
Lau, H. [2 ]
机构：
[1] Pharsight Corp, Montreal, PQ, Canada
[2] Celgene Corp, Summit, NJ USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2011年 / 89卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S90 / S90
页数：1
相关论文
共 50 条
  • [41] IS THE CLINICAL AND THERAPEUTIC PROFILE RELATED TO SATISFACTORY RESPONSE TO APREMILAST IN PSORIATIC ARTHRITIS?
    De la Morena, I
    Espinosa, M.
    Godoy, H.
    Martinez, A.
    Santos, C.
    Martinez, A.
    Fernandez, M.
    Fernandez-Llanio, N.
    Palma, D.
    Moreno, M. J.
    Haro, A.
    Conesa, A.
    Calvo, J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (04) : 730 - 730
  • [42] IS THE CLINICAL AND THERAPEUTIC PROFILE RELATED TO SATISFACTORY RESPONSE TO APREMILAST IN PSORIATIC ARTHRITIS?
    de la Morena, Isabel
    Espinosa, Maria
    Godoy Tunidor, Hilda
    Martinez-Ferrer, A.
    Ramirez, Carlos Santos
    Martinez, Anna
    Fernandez Matilla, Meritxell
    Fernandez-Llanio, Nagore
    Palma Sanchez, Deseada
    Jose Moreno, Maria
    Haro, Ana
    Conesa, Arantxa
    Calvo, Javier
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 903 - 903
  • [43] Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis
    Phyllis Chan
    Jiajie Yu
    Leslie Chinn
    Marita Prohn
    Jan Huisman
    Brett Matzuka
    William Hanley
    Katie Tuckwell
    Angelica Quartino
    Pharmaceutical Research, 2020, 37 (2)
  • [44] The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence
    Sideris, Eleftherios
    Corbett, Mark
    Palmer, Stephen
    Woolacott, Nerys
    Bojke, Laura
    PHARMACOECONOMICS, 2016, 34 (11) : 1101 - 1110
  • [45] The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence
    Eleftherios Sideris
    Mark Corbett
    Stephen Palmer
    Nerys Woolacott
    Laura Bojke
    PharmacoEconomics, 2016, 34 : 1101 - 1110
  • [46] Population Pharmacokinetics and Exposure-Response Analyses for CPX-351 in Patients With Hematologic Malignancies
    Wang, Qi
    Banerjee, Kamalika
    Vasilinin, Grygoriy
    Marier, J. F.
    Gibbons, Jacqueline A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (05): : 748 - 762
  • [47] Population Pharmacokinetic Modeling and Exposure-Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia
    Wang, Xiaofeng
    Raoufinia, Arash
    Bihorel, Sebastien
    Passarell, Julie
    Mallikaarjun, Suresh
    Phillips, Luann
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (02): : 150 - 164
  • [48] Population pharmacokinetics and exposure-response analyses for efficacy and safety of apadacitinib in patients with axial Spondyloarthritis
    Bhatnagar, Sumit
    Eckert, Doerthe
    Stodtmann, Sven
    Song, In-Ho
    Wung, Peter
    Liu, Wei
    Mohamed, Mohamed-Eslam F.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (02):
  • [49] Population Pharmacokinetic and Exposure-Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia
    Moser, Brian A.
    LaBell, Elizabeth S.
    Chigutsa, Emmanuel
    Jakubowski, Joseph A.
    Small, David S.
    CLINICAL PHARMACOKINETICS, 2018, 57 (02) : 243 - 254
  • [50] Exposure-Response Analyses of Virologic Response to Glecaprevir and Pibrentasvir in HCV Subjects from Phase 2 and 3 Studies
    Lin, Chih-Wei
    Wang, Haoyu
    Jiang, Qi
    Hosmane, Balakrishna
    Shulman, Nancy S.
    Mensa, Federico J.
    Liu, Wei
    HEPATOLOGY, 2017, 66 : 638A - 639A
12345